About The Gazette Search Back Issues Contact Us    
The newspaper of The Johns Hopkins University September 4, 2007 | Vol. 37 No. 1
Experimental Anti-Cancer Drug Kills Brain Tumor Stem Cells

By Leah R. Young
Johns Hopkins Medicine

A drug that shuts down a critical cell signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

In a series of laboratory and animal experiments, Johns Hopkins scientists blocked the signaling system, known as Hedgehog, with an experimental compound called cyclopamine to explore the blockade's effect on cancer stem cells that populate glioblastoma multiforme. Cyclopamine has long been known to inhibit Hedgehog signaling.

The scientists reported their findings in the journal Stem Cells published online July 19.

"Our study lends evidence to the idea that the lack of effective therapies for glioblastoma may be due to the survival of a rare population of cancer stem cells that appear immune to conventional radiation and chemotherapy," said Charles G. Eberhart, associate professor of pathology, ophthalmology and oncology in the School of Medicine, who led the work. "Hedgehog inhibition kills these cancer stem cells and prevents cancer from growing, and may thus develop into the first stem cell-directed therapy for glioblastoma."

Eberhart cautioned that while his study appears to prove the principle of Hedgehog blocking, much work remains before cyclopamine or any similar drug can be tested in patients. Scientists must determine whether the drug can be effectively and safely delivered to the whole body or whether it must go into the brain, and what, if any, adverse impact on normal stem cells the treatment might cause.

The new study adds to the growing evidence that only a small percentage of cancer cells — in this case, stem cells — are capable of unlimited self-renewal and that these cells alone power a tumor's growth.

Eberhart focused on two pathways important to the survival of normal brain stem cells, Hedgehog and Notch, suspecting that brain cancer stem cells cannot live without them.

The Hedgehog gene plays a major role in controlling normal fetal and postnatal development and, later in life, in helping normal adult stem cells function and proliferate.

The Johns Hopkins scientists first tested 19 human glioblastomas, removed during surgery and frozen immediately, and found Hedgehog active in five at the time of tumor removal. They also found Hedgehog activity in four of seven glioblastoma cell lines.

Next, the team used cyclopamine, chemically extracted from corn lilies that grow in the Rocky Mountains, to inhibit Hedgehog in cell lines growing on plastic or as neurospheres, round clusters of stem cells that float in liquid nutrients. This reduced tumor growth in the cell-laden plastic by 40 percent to 60 percent and caused the neurospheres to fall apart without any new growth of the cell clusters.

The researchers also pre-treated mice with cyclopamine before injecting human glioblastoma cells into their brains, resulting in cancer cells that failed to form tumors in the mice.

Other researchers have shown that radiotherapy fails to kill all cancer stem cells in glioblastomas, apparently because many of these cells can repair the DNA damage inflicted by radiation. The Johns Hopkins team suggests that blocking the Hedgehog pathway with cyclopamine kills these radiation-resistant cancer stem cells.

In previous laboratory experiments, Eberhart used cyclopamine to block Hedgehog using medulloblastoma cells, the most common brain cancer occurring in children.

Along with childhood brain cancers, cyclopamine has shown early promise in treating skin cancer; rhabdomyosarcoma, a muscle tumor; and multiple myeloma, a cancer of the white blood cells in bone marrow.

"What excites me is that we have taken things we learned about Hedgehog signaling in these relatively rare childhood brain tumors and translated them into an even more aggressive adult tumor," Eberhart said.

More than 10,000 Americans die annually from glioblastomas. Radiation is the standard therapy for the disease, and several years ago the U.S. Food and Drug Administration approved adding the drug temozolomide to radiotherapy because the combination provided a small survival increase.

First author Eli E. Bar, a postdoctoral fellow, said, "This is an incredibly difficult tumor to treat. Survival for glioblastoma has not changed much in 30 years. With the addition of temozolomide, survival got bumped from 12 months to 14 or 15 months."

This study was funded by the nonprofit Brain Tumors Funders' Collaborative, which is supported by eight private philanthropic and advocacy organizations.

Additional authors are Aneeka Chaudhry, Alex Lin, Xing Fan, Karisa Schreck, William Matsui and Alessandro Olivi, all of Johns Hopkins; and Angelo L. Vescovi, of the University of Milan Bicocca, and Francesco DeMeco, of the Istituto Nazionale Neurologico Carlo Besta, both in Milan, Italy.


The Gazette | The Johns Hopkins University | Suite 540 | 901 S. Bond St. | Baltimore, MD 21231 | 443-287-9900 |